David A Cory

Title: The Innovations of David A. Cory in Hepatitis Delta Virus Treatment

Introduction

David A. Cory, a prominent inventor based in Palo Alto, California, has made significant contributions to the field of medicinal treatment, particularly focusing on hepatitis delta virus (HDV) infection. With a total of seven patents to his name, David has been at the forefront of developing innovative therapies aimed at reducing the viral loads of HDV in patients.

Latest Patents

Among his most recent patents, David A. Cory has developed methods centered on the treatment of hepatitis delta virus infection. His work includes a dual therapy approach that comprises the use of lonafarnib-ritonavir co-therapy. In some embodiments, this innovative method is further enhanced by the addition of interferon treatment, showcasing his dedication to advancing medical science in this challenging area.

Career Highlights

Throughout his career, David has held essential positions in notable biopharmaceutical companies such as Eiger Biopharmaceuticals, Inc. and Eit Pharma, Inc. His involvement in these organizations has allowed him to work on groundbreaking research and translate his innovative ideas into practical applications that have the potential to significantly impact patient care.

Collaborations

In his journey as an inventor, David has collaborated with esteemed professionals in the field, including Jeffrey S. Glenn and Ingrid Choong. These collaborations highlight his commitment to teamwork and the exchange of ideas, which are critical in the advancement of scientific research and innovation.

Conclusion

David A. Cory's work epitomizes the spirit of innovation in the medical field, particularly in the fight against hepatitis delta virus infection. With a robust portfolio of patents and collaborations with other leading experts, he continues to pave the way for new treatment methodologies that can alleviate the burden of this viral infection on patients worldwide.